Scienza e Tecnologia
First Patient Dosed in Italian Named Patient (Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent
This follows the completion of Telix's successful global Phase III ZIRCON study ( Zi rconium in R enal C ancer On cology, ClinicalTrials.gov Identifier: NCT03849118), which reported positive results in November 2022 , meeting all co-primary and secondary endpoints.
Arturo Chiti , Professor in Diagnostic Imaging and Radiotherapy at IRCCS Ospedale San Raffaele commented, "Continued access in Europe to TLX250-CDx is vitally important to enable early detection of ccRCC, which can often be challenging and reliant on invasive biopsy and nephrectomy (kidney removal). In TLX250-CDx, I am extremely pleased to be able to offer a non-invasive 'Molecular Biopsy™' to address unmet need in my patients in Italy ."
Frédéric Fantino, Telix Medical Director for the Europe , Middle East and Africa (EMEA) region continued, "We are pleased to support unmet patient need by adding a second European country to Telix's global expanded access program for TLX250-CDx. Through the ZIRCON study, this investigational agent has demonstrated high sensitivity and specificity in the detection of ccRCC with potential to change standard of care in the diagnosis and management of this most aggressive form of kidney cancer."
In Italy , the use of a medicinal product in an individual patient prior to marketing authorisation and outside the context of a clinical trial is permitted in exceptional circumstances and regulated by the Ministry of Health.
Italy becomes the third active country in Telix's global expanded access program, where first patients were dosed in the Netherlands and the United States (U.S.) in December 2023 . Telix has commenced the regulatory filing for TLX250-CDx (Zircaix™ ) with the U.S. Food and Drug Administration (FDA) under a Biologics License Application (BLA) rolling submission and is progressing other equivalent applications with regulatory agencies in key commercial jurisdictions.
Physicians in Europe who may have eligible patients can email eap-emea@telixpharma.com for further information about TLX250-CDx named patient access. For more information about ongoing clinical trials of TLX250-CDx, please visit https://telixpharma.com/our-portfolio/clinical-trials/
Telix's Policy on Offering Compassionate Use to Investigational Medicines can be downloaded at the following link.
Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. Telix is headquartered in Melbourne, Australia , with international operations in the United States , Europe ( Belgium and Switzerland ), and Japan . Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).
Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on X and LinkedIn.
TLX250-CDx has not received a marketing authorisation in any jurisdiction. Telix's lead imaging product, gallium-68 ( Ga) gozetotide (also known as Ga PSMA-11) injection, has been approved by the FDA, by the Australian Therapeutic Goods Administration (TGA), and by Health Canada.
Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Corporate Communications and Investor Relations
Email: kyahn.williamson@telixpharma.com
Legal Notices
[1] Trade name subject to final regulatory approval.
[2] Telix ASX disclosure 7 November 2022 .
[3] Telix media release 4 December 2023 .
[4] Telix media release 11 December 2023 .
[5] Telix ASX disclosure 19 December 2023 .
[6] Telix ASX disclosure 20 December 2021 .
[7] Telix ASX disclosure 2 November 2021 .
[8] Telix ASX disclosure 14 October 2022 .
Logo - https://mma.prnewswire.com/media/1920208/4609020/TeliMain_Logo_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/first-patient-dosed-in-italian-named-patient-early-access-program-for-tlx250-cdx-telixs-kidney-cancer-imaging-agent-302097967.html